News
Feed
Events
Feed
News
+ Events
Feed

Antengene

  • Country Hong Kong

Latest News

15 November 2021

08:15 Corporate

Antengene

Corporate

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

15 September 2021

09:14 Corporate

Antengene

Corporate

Antengene Selected as a Constituent of the FTSE Global Equity Index Series

18 May 2021

04:12 Corporate

Antengene

Corporate

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

29 April 2021

05:36 Corporate

Antengene

Corporate

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

15 March 2021

08:28 Corporate

Antengene

Corporate

Antengene Included in the Shenzhen-Hong Kong Stock Connect

1 March 2021

08:36 Corporate

Antengene

Corporate

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Index-es Including the Hang Seng Composite Index

28 January 2021

03:33 Corporate

Antengene

Corporate

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

21 December 2020

08:21 Corporate

Antengene

Corporate

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

7 December 2020

07:07 Corporate

Antengene

Corporate

Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

3 December 2020

10:27 Corporate

Antengene

Corporate

Antengene Submits NDAs for XPOVIO(R) (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

26 November 2020

05:21 Corporate

Antengene

Corporate

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

9 November 2020

04:15 Corporate

Antengene

Corporate

Antengene Corporation Limited Announces Proposed Listing on the Main Board of SEHK Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Near-term Commercialization Launch Prospects of Core Products Offer price between HK$15.80 and HK$18.08 per share

15 October 2020

09:01 Corporate

Antengene

Corporate

Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

Upcoming Events

No Events found